Related content

Bevacizumab: A Review of its Use in Advanced Colorectal Cancer, Breast Cancer, and NSCLC

By Lyseng-Williamson Katherine A.   Robinson Dean M.  

American Journal of Cancer, Vol. 5, Iss. 1, 2006-01 ,pp. : 43-60

Adis International

Access to resources Recommend Favorite

Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC

By Reck Martin  

Future Oncology, Vol. 2, Iss. 1, 2006-02 ,pp. : 47-51

Future Medicine

Access to resources Recommend Favorite

A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer

By Petrelli Fausto  

Breast Cancer, Vol. 18, Iss. 3, 2011-07 ,pp. : 226-230

Springer Publishing Company

Access to resources Recommend Favorite

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer

By Kusaba Hitoshi   Esaki Taito   Kishimoto Junji   Uchino Keita   Arita Shuji   Kumagai Hozumi   Mitsugi Kenji   Akashi Koichi   Baba Eishi  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 29-34

Springer Publishing Company

Access to resources Recommend Favorite